Blueprint Medicines Corp Stock Price on December 11, 2024
| BPMC Stock | USD 89.40 2.22 2.42% |
Below is the normalized historical share price chart for Blueprint Medicines Corp extending back to April 30, 2015. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Blueprint Medicines stands at 89.40, as last reported on the 29th of December, with the highest price reaching 91.20 and the lowest price hitting 87.24 during the day.
If you're considering investing in Blueprint Stock, it is important to understand the factors that can impact its price. Blueprint Medicines Corp secures Sharpe Ratio (or Efficiency) of -0.0117, which signifies that the company had a -0.0117% return per unit of risk over the last 3 months. Blueprint Medicines Corp exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Blueprint Medicines' Risk Adjusted Performance of 0.0298, downside deviation of 2.51, and Mean Deviation of 1.67 to double-check the risk estimate we provide.
The current year's Stock Based Compensation To Revenue is expected to grow to 0.52, whereas Total Stockholder Equity is forecasted to decline to about 124.1 M. . At present, Blueprint Medicines' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 44.91, whereas Price To Sales Ratio is forecasted to decline to 21.28. Blueprint Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 30th of April 2015 | 200 Day MA 96.6932 | 50 Day MA 92.4674 | Beta 0.59 |
Blueprint |
Sharpe Ratio = -0.0117
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BPMC |
Estimated Market Risk
| 2.31 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Blueprint Medicines is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Blueprint Medicines by adding Blueprint Medicines to a well-diversified portfolio.
Price Book 18.1359 | Enterprise Value Ebitda (11.22) | Price Sales 13.0732 | Shares Float 62.8 M | Wall Street Target Price 125.579 |
Related Headline
PTC Therapeutics Headline on 11th of December 2024
PTC Therapeutics Ends Utreloxastat Development After Rare Ne... by benzinga.com
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntingtons and PKU programs.
Blueprint Medicines Valuation on December 11, 2024
It is possible to determine the worth of Blueprint Medicines on a given historical date. On December 11, 2024 Blueprint was worth 95.32 at the beginning of the trading date compared to the closed value of 94.47. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Blueprint Medicines stock. Still, in general, we apply an absolute valuation method to find Blueprint Medicines' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Blueprint Medicines where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Blueprint Medicines' related companies.
| Open | High | Low | Close | Volume | |
| 95.23 | 97.44 | 94.47 | 95.39 | 437,040 | |
12/11/2024 | 95.32 | 97.00 | 93.41 | 94.47 | 540,884 |
| 94.13 | 94.91 | 92.17 | 92.58 | 1,213,287 |
| Backtest Blueprint Medicines | | | Blueprint Medicines History | | | Blueprint Medicines Valuation | Previous | Next |
Blueprint Medicines Trading Date Momentum on December 11, 2024
| On December 12 2024 Blueprint Medicines Corp was traded for 92.58 at the closing time. The top price for the day was 94.91 and the lowest listed price was 92.17 . The trading volume for the day was 1.2 M. The trading history from December 12, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 2.00% . The overall trading delta against the current closing price is 5.06% . |
Blueprint Medicines Corp Fundamentals Correlations and Trends
By evaluating Blueprint Medicines' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Blueprint Medicines' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Blueprint financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Blueprint Medicines Stock history
Blueprint Medicines investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Blueprint is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Blueprint Medicines Corp will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Blueprint Medicines stock prices may prove useful in developing a viable investing in Blueprint Medicines
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 60.6 M | 43.6 M | |
| Net Loss | -501.8 M | -476.7 M |
Blueprint Medicines Quarterly Net Working Capital |
|
Blueprint Medicines Stock Technical Analysis
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Blueprint Medicines Period Price Range
Low | December 29, 2024
| High |
0.00 | 0.00 |
Blueprint Medicines Corp cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Blueprint Medicines December 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Blueprint Medicines shares will generate the highest return on investment. By undertsting and applying Blueprint Medicines stock market strength indicators, traders can identify Blueprint Medicines Corp entry and exit signals to maximize returns
Blueprint Medicines Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Blueprint Medicines' price direction in advance. Along with the technical and fundamental analysis of Blueprint Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Blueprint to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0298 | |||
| Jensen Alpha | 0.0547 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0144 | |||
| Treynor Ratio | 0.3648 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |